The FDA’s Identity Crisis: Marty Makary, Mass Layoffs,and the Trump-Era Push for Speed Over Safety
The U.S. Food and Drug Administration (FDA) has entered a defining period of uncertainty.
Under the leadership of its new Commissioner, Dr. Marty Makary, the agency is experiencing a
wave of profound internal disruption—marked most visibly by sweeping layoffs that have gutted
key divisions responsible for drug and device evaluation.
Makary, a prominent surgeon and health policy expert known for his reformist views, has
stepped into the role during a politically charged moment. As former President Donald Trump
once again dominates the GOP primary and seeks a return to the White House, federal agencies
like the FDA are feeling the heat of a renewed push toward deregulation and speed.
The problem? These job cuts—over 1,200 positions across critical units—have raised alarm bells
among experts who worry that fewer staff means fewer safety checks, less transparency, and a
diminished capacity to uphold the FDA’s core mission: protecting public health.
A Troubled Start
Makary’s appointment was initially met with cautious optimism. He has long criticized
inefficiency in American healthcare and advocated for better transparency in pricing and
outcomes. His book, The Price We Pay, made waves for exposing exploitative medical billing
practices and calling for patient-first reforms.
But leading a bureaucracy as complex as the FDA requires more than bold ideas—it demands a
steady hand, deep institutional understanding, and the ability to inspire trust from a workforce
now rocked by uncertainty.
Within weeks of taking the reins, Makary oversaw budget cuts that led to significant job losses.
While his team has characterized the move as a “streamlining” initiative, critics view it as the
start of a deeper, more troubling transformation of the FDA’s role—from public watchdog to
political instrument.
Trump’s Shadow Looms Large
The layoffs come amid growing pressure from the political right to cut “government red tape.”
Trump’s first term in office saw a rapid acceleration in regulatory rollbacks, from environmental
protections to labor laws. The FDA wasn’t spared—Operation Warp Speed, for instance,
prioritized fast-tracking vaccine development, drawing both praise and criticism.
Now, with Trump once again leading in national Republican polls, agencies are bracing for
another round of aggressive deregulation.
In this context, Makary’s appointment makes strategic sense to Trump-aligned forces: he’s a
known critic of government waste and a media-savvy figure who can deliver reform messaging
with credibility. But their alliance may be tenuous.
While Makary and Trump share a distaste for bureaucracy, their motivations are markedly
different. Trump has often acted from political expedience, valuing loyalty over expertise.
Makary, conversely, has built his career on data-driven reform and open dialogue. If pushed to
prioritize political optics over scientific rigor, the Commissioner may find himself at odds with
his supposed allies.
Erosion of Transparency
One of the most worrying consequences of the layoffs is the loss of institutional oversight.
Departments tasked with internal audits, FOIA compliance, and stakeholder communication have
been hit hard. With fewer people to vet public records requests or conduct post-market
surveillance, the FDA risks becoming opaque—exactly when transparency is needed most.
This is especially dangerous in the age of misinformation. A shrinking, less communicative FDA
is more vulnerable to public mistrust, conspiracy theories, and diminished legitimacy. And when
that trust breaks down, so does compliance with public health guidance.
Makary has attempted to counter these concerns by launching tech-based solutions like a public-
facing drug approval dashboard. Yet, flashy dashboards cannot replace the value of human
oversight and professional judgment—qualities now in shorter supply.
A Faster FDA—But at What Cost?
Makary’s tenure also comes with a push for speed. His team has announced plans to shorten the
drug review timeline by 25% and roll out AI-powered tools to aid in trial assessments.
Supporters within the pharmaceutical industry are hopeful, citing long-standing frustrations with
FDA bottlenecks that can delay innovation.
But there’s a fine line between efficient and reckless.
“There’s a reason the FDA moves cautiously,” says Dr. Steven Rosenfeld, a former official with
the agency’s oncology review division. “A bad approval doesn’t just hurt a company’s stock—it
can ruin lives.”
Public health must never be compromised for the sake of political optics or industry
convenience. It’s true that some FDA processes have needed modernization, and Makary’s
emphasis on patient-first innovation is commendable. But if this new speed comes without
sufficient review, the cost could be far greater than a delayed product launch.
Inside the Makary Playbook
Dr. Makary is not a bureaucrat by nature. He’s a surgeon, a professor, and a best-selling author.
He is articulate, media-friendly, and unafraid to challenge sacred cows. That approach has earned
him admiration among reformers—but not always among rank-and-file agency staff.
“He’s not someone who thrives on consensus,” said one former FDA staffer. “He comes in with
a vision and expects others to catch up.”
This style can either drive much-needed innovation or alienate the very professionals who know
the agency best. Whether Makary succeeds may depend not just on policy, but on his ability to
lead through empathy and inclusion.
It also remains to be seen how Trump and his political allies respond if Makary’s scientific
compass conflicts with their broader agenda. As history has shown, those who stand in the way
of Trump’s ambitions rarely last long in their roles.
What’s at Stake
The FDA is not just another agency—it is the final checkpoint between the public and the
products they rely on for survival. Insulin, chemotherapy drugs, pacemakers, and countless other
life-saving tools pass through its regulatory gate.
Weakening the FDA doesn’t just threaten those gates—it threatens lives.
For years, the agency has wrestled with the dual mandate of fostering innovation while
maintaining rigorous safety standards. That balance is already delicate. Understaffing it during a
politically charged deregulatory push may tip it toward catastrophe.
Final Thoughts
Dr. Marty Makary has both the intellect and integrity to make lasting reforms to the FDA. His
career proves he’s no ideologue—he’s a public health advocate at heart. But the context in which
he now operates is fraught with complexity, political landmines, and public skepticism.
If he’s to succeed, he’ll need more than policy tweaks. He’ll need to rebuild morale, defend
scientific integrity, and resist becoming a pawn in a larger political game.
Layoffs and budget cuts may be sold as efficiency, but without the staff and support necessary to
fulfill its mandate, the FDA is at risk of losing the very identity that has made it one of the most
trusted institutions in American life.
The stakes could not be higher.
